D.D., W., L., M., M.P., W., V.H.F., L., H., Y., & HEALTH, S. S. H. S. O. P. (2019). Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments.

D.D., Wang, Ma L., Wong M.P., Lee V.H.F., Yan H., و SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-induced Gefitinib- and Erlotinib-resistance in Non-small-cell Lung Carcinoma Treatments. 2019.

D.D., Wang, et al. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-induced Gefitinib- and Erlotinib-resistance in Non-small-cell Lung Carcinoma Treatments. 2019.